drugset / Trial / NCT06262139
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
NaSequentialOpen-labelDiagnostic
Summary
This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.
Timeline
- Start
- 2024-07-25
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT218 | Unknown | 0.02 mmol | Intravenous |
| Subject | MT218 | Unknown | 0.04 mmol | Intravenous |
| Subject | MT218 | Unknown | 0.06 mmol | Intravenous |
Indications
No indication recorded.